Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ET-743.

Risto S Cvetkovic1, David P Figgitt, Greg L Plosker

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 16, 2002
PubMed
Summary
This summary is machine-generated.

Ecteinascidin 743 (ET-743), a marine-derived DNA-binding agent, shows promise in treating advanced soft tissue sarcomas (STS). Clinical trials indicate durable tumor responses and manageable toxicities, suggesting its potential as an effective antineoplastic therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Marine Biotechnology

Background:

  • Ecteinascidin 743 (ET-743) is a novel DNA-binding antineoplastic agent derived from the marine tunicate Ecteinascidia turbinata.
  • ET-743 exhibits significant in vitro cytotoxic activity against various cancer types, including soft tissue sarcomas (STS), melanoma, and carcinomas of the breast, ovary, colon, kidney, lung, and prostate.

Purpose of the Study:

  • To evaluate the efficacy and safety of ET-743 in patients with advanced soft tissue sarcomas (STS).
  • To investigate the unique mechanism of action of ET-743, including its effects on DNA repair, cell cycle progression, apoptosis, and multidrug resistance (MDR1) gene expression.

Main Methods:

  • Three multicenter Phase II clinical trials were conducted to assess ET-743 efficacy in advanced STS patients.

Related Experiment Videos

  • Pooled analysis of trial data included response rates, duration of response, overall survival, and progression-free survival.
  • Adverse events were systematically recorded to evaluate the safety profile of ET-743.

    • Main Results:

    • Partial tumor response rates ranged from 6-8% for second/third-line treatment and 18% for first-line chemotherapy.
    • 42-50% of patients achieved stable disease, with durable responses up to 14 months.
    • Median overall survival was 10.2 months, with a 1-year survival rate of 40% and a 6-month progression-free rate of 27.2%.

    Conclusions:

    • ET-743 demonstrates notable efficacy in advanced STS, with durable responses and encouraging survival outcomes.
    • The drug is generally well-tolerated, with manageable hematological and hepatic toxicities being the most common adverse events.
    • ET-743's unique mechanism of action, including inhibition of transcription-dependent repair and MDR1 gene expression, contributes to its antineoplastic activity.